AnaptysBio (NASDAQ: ANAB) CLO reports RSU vesting and tax share sale

Rhea-AI Filing Summary

AnaptysBio chief legal officer Eric Loumeau reported RSU vesting and a related tax sale of shares. On January 7, 2026, 5,888 restricted stock units were converted into the same number of shares of AnaptysBio common stock at an exercise price of $0, reflecting that each RSU settles into one share for no cash consideration. After this transaction, Loumeau held 15,045 shares of common stock directly.

On January 8, 2026, he sold 2,210 shares of common stock at a price of $44.71 per share. The filing explains that this sale was executed solely to cover tax withholding obligations arising from the RSU vesting through a “sell to cover” transaction and was not a discretionary sale. Following the sale, Loumeau directly owned 12,835 shares of common stock and 17,662 RSUs that continue to vest in 25% annual increments starting January 7, 2026, contingent on continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LOUMEAU ERIC J

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF LEGAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		M		5,888	A	(1)	15,045	D
Common Stock	01/08/2026		S(2)		2,210	D	$44.71	12,835	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	01/07/2026		M			5,888	(3)	(3)	Common Stock	5,888	$0	17,662	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

3. The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Eric Loumeau	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did AnaptysBio (ANAB) report for Eric Loumeau?

The chief legal officer, Eric Loumeau, reported the vesting and settlement of 5,888 restricted stock units (RSUs) into common shares on January 7, 2026, followed by the sale of 2,210 shares of AnaptysBio common stock on January 8, 2026.

How many AnaptysBio shares did Eric Loumeau sell and at what price?

On January 8, 2026, Eric Loumeau sold 2,210 shares of AnaptysBio common stock at a price of $44.71 per share, as disclosed in the Form 4.

Why did AnaptysBio’s chief legal officer sell shares according to the Form 4?

The Form 4 states that the 2,210-share sale was made to cover tax withholding obligations related to the vesting and settlement of RSUs through a “sell to cover” transaction, and it does not represent a discretionary transaction by the reporting person.

What are the terms of Eric Loumeau’s RSUs reported in this filing?

Each RSU gives a contingent right to receive 1 share of AnaptysBio common stock for no cash consideration upon settlement. The RSUs vest as to 25% of the total RSUs annually starting on January 7, 2026, subject to Loumeau’s continued service on each vesting date.

How many AnaptysBio shares does Eric Loumeau own after these transactions?

After the reported transactions, Eric Loumeau directly owned 12,835 shares of AnaptysBio common stock and 17,662 RSUs, as stated in the beneficial ownership columns of the Form 4.

What positions does the reporting person hold at AnaptysBio (ANAB)?

The reporting person, Eric Loumeau, is identified as an officer of AnaptysBio with the title Chief Legal Officer, and is not listed as a director or 10% owner in this filing.